February 12, 2018

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

CLOSURES AND SUSPENSIONS
COLORECTAL
NRG-GI002: URGENT! TIME-SENSITIVE! Temporary suspension of accrual is effective today, Monday, February 12, at 4pm ET. A memo is posted on CTSU.

FORM UPDATES
SARCOMA
NRG-DT001: The NRG-DT001 Specimen Transmittal Form for NRG PK and PD Samples has been replaced with the following transmittal forms on the NRG website: AMG-232 Plasma PK-thru 4Xweek; MIC 1-thru 4Xweek; AMG-232 Plasma PK-5Xweek; MIC 1-5Xweek. Use the new forms effective immediately.

OTHER PROTOCOL NOTICES
1. NRG Oncology DMC (Panel A and Panel B) Meeting Excerpts have been posted
For studies on the CTSU menu, excerpts can be found on individual protocol pages on the  CTSU website. (Note: A list of studies with excerpts posted on CTSU can be found on the DMC page on the NRG Oncology website and under Protocol Updates on the  CTSU website). Excerpts for studies that are not on the CTSU menu are posted on the DMC page on the NRG Oncology website.

2. GASTROINTESTINAL
RTOG 1112: The current Spanish-translated consent form is now available on CTSU.

3. GENITOURINARY
NRG-GU005: The patient brochure is now available on CTSU.

4. VTOC TRAINING
The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for February 14, 2018.

DRUG SAFETY UPDATES AND INVESTIGATORS BROCHURE NOTICES
Safety updates have been issued for NSABP legacy studies. For details, please see the NSABP E-mail Distributions page and CTSU.

Safety updates have been issued for the following NRG Oncology studies:
- Cabozantinib: NRG-GY001

  • For NRG-GY001 safety reports, please see CTSU.

An Investigator’s Brochure notice has been issued for the following studies:
-Pazopanib (RTOG 0912)
-Lapatinib (RTOG 1119)

The current version of the Investigator Brochure Documents (Investigator Brochure, Summary of Changes) for Lapatinib (GW572016) NSC 727989 and for Pazopanib (GW786034) NSC 737754 for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website ( https://eapps-ctep.nci.nih.gov/OAOP/pages/login.jspx). Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

 

President's Day Closure Information
Please note that the following NRG Oncology locations will be closed in observance of President's Day on Monday, February 19, 2018: Philadelphia East Operations Center, Buffalo SDMC, and the Biospecimen Bank in San Francisco. All other locations will be open during regular business hours on that day.

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES
Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN,Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK,Hartford AC, Kim HE, Won M, Curran WJ Jr. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol. 2018 Feb 5. doi: 10.1007/s11060-017-2558-x. [Epub ahead of print] PubMed PMID: 29404979. Read more

PUBLICATIONS REMINDERS
Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings
Society of Gynecologic Oncology (SGO); Mar 24-27, 2018; New Orleans, LA

Society of Surgical Oncology (SSO); Mar 21-24, 2018; Chicago, IL

St. Gallen GI Cancer Conference; Mar 15-17, 2018; St Gallen, Switzerland

United States and Canadian Academy of Pathology (USCAP); Mar 17-24, 2018; Seattle, WA

Upcoming Abstract Submission Deadlines
American Association for Cancer Research (AACR); Apr 14-18, 2018; Chicago, IL; Final data for placeholder abstracts due Feb 23, 2018

American Association of Physicists in Medicine (AAPM); Jul 29 - Aug 2, 2018; Nashville, TN; due to publications committee Feb 28, 2018; meeting abstracts submission deadline Mar 8, 2018

American Society of Clinical Oncology (ASCO); Jun 1-5, 2018; Chicago, IL; meeting abstracts submission deadline Feb 13, 2018; Late-breaking Mar 15, 2018

American Society for Radiation Oncology (ASTRO); Oct 21-24, 2018; San Diego, CA; meeting abstracts submission deadline Feb, 14 2018; Late-breaking Aug 1, 2018

College of American Pathologists (CAP); Oct 20–24, 2018; Chicago, IL; due to publications committee Feb 23, 2018; meeting abstracts submission deadline Mar 9, 2018

Multinational Association of Supportive Care in Cancer (MASCC); Jun 28-30, 2018; Vienna, Austria; Late-breaking due Apr 22, 2018 


NRG Oncology is proud to be an active participant of #CancerMoonShot.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address